trial

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

NCTId NCT05669742
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 40 (estimated)
Sponsored by Tanta University
Primary completion 2026-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2023-05-25
Primary completion
2026-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
EmpagliflozinOlanzapine

Sponsors

Tanta UniversityLead Sponsor

Sites

1 total
Tanta, Egypt

Linked catalysts

1
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olan — primary completion2026-06

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE3
Primary Completion Date
2026-06
Status
RECRUITING
relationships
The graph out of here
drug
Empagliflozin
drug
Olanzapine
drug
lead_sponsor
Tanta University
company
indication
Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
indication